(RTTNews) – Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi have announced that the European Commission has extended the marketing authorisation for Dupixent (dupilumab) in the European Union for 6- to 11-year-olds with severe atopic dermatitis requesting therapy.
“This approval of Dupixent in the EU represents a first step forward for young people with severe atopic dermatitis and their families, who spend countless days and nights dealing with their child’s disease with few remedy characteristics to help alleviate debilitating symptoms,” said George Yancopoulos, President and Chief Scientific Officer of Regeneron.
Dupixent is an all-human monoclonal antibody, which was invented by Regeneron’s VelocImmune technology and has been developed jointly through Regeneron and Sanofi as a component of a global collaboration agreement.